Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Key Points Amgen offers an attractive dividend and significant upside potential. Vertex Pharmaceuticals is a great biotech ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...